Rapamycin nanoparticles localize in diseased lung vasculature and prevent pulmonary arterial hypertension

International Journal of Pharmaceutics

Volumn 524, Issue 1-2, 2017, Pages 257-267

  Segura Ibarra, Victor ^a,b   Amione Guerra, Javier ^c   Cruz Solbes, Ana S ^c   Cara, Francisca E ^a   Iruegas Nunez, David A ^a,b   Wu, Suhong ^a   Youker, Keith A ^c   Bhimaraj, Arvind ^c   Torre Amione, Guillermo ^b,c   Ferrari, Mauro ^a,d   Karmouty Quintana, Harry ^e   Guha, Ashrith ^c   Blanco, Elvin ^a  

^a HOUSTON METHODIST RESEARCH INSTITUTE   (United States)

^b SCHOOL OF ENGINEERING AND SCIENCES   (Mexico)

^c HOUSTON METHODIST HOSPITAL   (United States)

^d WEILL CORNELL MEDICAL COLLEGE   (United States)

^e UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

Drug delivery; Endothelial dysfunction; Polymer nanoparticles; Pulmonary arterial hypertension; Rapamycin; Vascular permeability

Indexed keywords

BETA ACTIN; MAMMALIAN TARGET OF RAPAMYCIN; MONOCROTALINE; NANOPARTICLE; POLY(ETHYLENE GLYCOL) BLOCK POLY(EPSILON CAPROLACTONE); POLYMER; PROTEIN S6; RAPAMYCIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERIOLE; ARTICLE; CONTROLLED STUDY; ENDOTHELIAL DYSFUNCTION; HEART RIGHT VENTRICLE PRESSURE; HEART VENTRICLE REMODELING; IN VIVO STUDY; LUNG; LUNG BLOOD VESSEL; MALE; NANOPHARMACEUTICS; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RAT; SYSTOLIC BLOOD PRESSURE; WEIGHT GAIN; WEIGHT REDUCTION; ANIMAL; DISEASE MODEL; DRUG EFFECTS; INTRAVENOUS DRUG ADMINISTRATION; PATHOLOGY; SPRAGUE DAWLEY RAT;

ADMINISTRATION, INTRAVENOUS; ANIMALS; DISEASE MODELS, ANIMAL; HYPERTENSION, PULMONARY; LUNG; NANOPARTICLES; RATS; RATS, SPRAGUE-DAWLEY; SIROLIMUS;

EID: 85017258950     PISSN: 03785173     EISSN: 18733476     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2017.03.069     Document Type: Article

References (50)

1. Ballou, L.M., Lin, R.Z., Rapamycin and mTOR kinase inhibitors. J. Chem. Biol. 1 (2008), 27–36.
2. Barenholz, Y., Doxil(R)–the first FDA-approved nano-drug: lessons learned. J. Control. Release 160 (2012), 117–134.
3. Blanco, E., Hsiao, A., Ruiz-Esparza, G.U., Landry, M.G., Meric-Bernstam, F., Ferrari, M., Molecular-targeted nanotherapies in cancer: enabling treatment specificity. Mol. Oncol. 5 (2011), 492–503.
4. Blanco, E., Sangai, T., Wu, S., Hsiao, A., Ruiz-Esparza, G.U., Gonzalez-Delgado, C.A., Cara, F.E., Granados-Principal, S., Evans, K.W., Akcakanat, A., Wang, Y., Do, K.-A., Meric-Bernstam, F., Ferrari, M., Colocalized delivery of Rapamycin and paclitaxel to tumors enhances synergistic targeting of the PI3K/Akt/mTOR pathway. Mol. Ther. 22 (2014), 1310–1319.
5. Chen, L., Nakano, K., Kimura, S., Matoba, T., Iwata, E., Miyagawa, M., Tsujimoto, H., Nagaoka, K., Kishimoto, J., Sunagawa, K., Egashira, K., Nanoparticle-mediated delivery of pitavastatin into lungs ameliorates the development and induces regression of monocrotaline-induced pulmonary artery hypertension. Hypertension 57 (2011), 343–350.
6. Coeytaux, R.R., Schmit, K.M., Kraft, B.D., Kosinski, A.S., Mingo, A.M., Vann, L.M., Gilstrap, D.L., Hargett, C.W., Heidenfelder, B., Dolor, R.J., McCrory, D.C., Comparative effectiveness and safety of drug therapy for pulmonary arterial hypertension: a systematic review and meta-analysis. Chest 145 (2014), 1055–1063.
7. Deblon, N., Bourgoin, L., Veyrat-Durebex, C., Peyrou, M., Vinciguerra, M., Caillon, A., Maeder, C., Fournier, M., Montet, X., Rohner-Jeanrenaud, F., Foti, M., Chronic mTOR inhibition by rapamycin induces muscle insulin resistance despite weight loss in rats. Br. J. Pharmacol. 165 (2012), 2325–2340.
8. Delcroix, M., Howard, L., Pulmonary arterial hypertension: the burden of disease and impact on quality of life. Eur. Respir. Rev. 24 (2015), 621–629.
9. Eddahibi, S., Raffestin, B., Hamon, M., Adnot, S., Is the serotonin transporter involved in the pathogenesis of pulmonary hypertension. J. Lab. Clin. Med. 139 (2002), 194–201.
10. Farber, H.W., Loscalzo, J., Pulmonary arterial hypertension. N. Engl. J. Med. 351 (2004), 1655–1665.
11. Fike, C.D., Dikalova, A., Kaplowitz, M.R., Cunningham, G., Summar, M., Aschner, J.L., Rescue treatment with L-citrulline inhibits hypoxia-induced pulmonary hypertension in newborn pigs. Am. J. Respir. Cell Mol. Biol. 53 (2014), 255–264.
12. Galie, N., Hoeper, M.M., Humbert, M., Torbicki, A., Vachiery, J.L., Barbera, J.A., Beghetti, M., Corris, P., Gaine, S., Gibbs, J.S., Gomez-Sanchez, M.A., Jondeau, G., Klepetko, W., Opitz, C., Peacock, A., Rubin, L., Zellweger, M., Simonneau, G., Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur. Heart J. 30 (2009), 2493–2537.
13. George, M.P., Champion, H.C., Pilewski, J.M., Lung transplantation for pulmonary hypertension. Pulm. Circ. 1 (2011), 182–191.
14. George, M.G., Schieb, L.J., Ayala, C., Talwalkar, A., Levant, S., Pulmonary hypertension surveillance: United States, 2001 to 2010. Chest 146 (2014), 476–495.
15. Goncharova, E.A., Ammit, A.J., Irani, C., Carroll, R.G., Eszterhas, A.J., Panettieri, R.A., Krymskaya, V.P., PI3K is required for proliferation and migration of human pulmonary vascular smooth muscle cells. Am. J. Physiol. Lung Cell. Mol. Physiol. 283 (2002), L354–363.
16. Goncharova, E.A., mTOR and vascular remodeling in lung diseases: current challenges and therapeutic prospects. FASEB J. 27 (2013), 1796–1807.
17. Gradishar, W.J., Tjulandin, S., Davidson, N., Shaw, H., Desai, N., Bhar, P., Hawkins, M., O'Shaughnessy, J., Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J. Clin. Oncol. 23 (2005), 7794–7803.
18. Gradishar, W.J., Albumin-bound paclitaxel: a next-generation taxane. Expert Opin. Pharmacother. 7 (2006), 1041–1053.
19. Guignabert, C., Tu, L., Le Hiress, M., Ricard, N., Sattler, C., Seferian, A., Huertas, A., Humbert, M., Montani, D., Pathogenesis of pulmonary arterial hypertension: lessons from cancer. Eur. Respir. Rev., 22, 2013, 543.
20. Hagiwara, H., Sunada, Y., Mechanism of taxane neurotoxicity. Breast Cancer 11 (2004), 82–85.
21. Hamilton, A., Biganzoli, L., Coleman, R., Mauriac, L., Hennebert, P., Awada, A., Nooij, M., Beex, L., Piccart, M., Van Hoorebeeck, I., Bruning, P., de Valeriola, D., EORTC 10968: a phase I clinical and pharmacokinetic study of polyethylene glycol liposomal doxorubicin (Caelyx, Doxil) at a 6-week interval in patients with metastatic breast cancer. Eur. Organ. Res. Treat. Cancer Ann. Oncol. 13 (2002), 910–918.
22. Handoko, M.L., de Man, F.S., Happé, C.M., Schalij, I., Musters, R.J.P., Westerhof, N., Postmus, P.E., Paulus, W.J., van der Laarse, W.J., Vonk-Noordegraaf, A., Opposite effects of training in rats with stable and progressive pulmonary hypertension. Circulation 120 (2009), 42–49.
23. Hawkins, M.J., Soon-Shiong, P., Desai, N., Protein nanoparticles as drug carriers in clinical medicine. Adv. Drug Deliv. Rev. 60 (2008), 876–885.
24. Hislop, A., Reid, L., Intra-pulmonary arterial development during fetal life-branching pattern and structure. J. Anat. 113 (1972), 35–48.
25. Houssaini, A., Abid, S., Mouraret, N., Wan, F., Rideau, D., Saker, M., Marcos, E., Tissot, C.-M., Dubois-Randé, J.-L., Amsellem, V., Adnot, S., Rapamycin reverses pulmonary artery smooth muscle cell proliferation in pulmonary hypertension. Am. J. Respir. Cell Mol. Biol. 48 (2013), 568–577.
26. Humar, R., Kiefer, F.N., Berns, H., Resink, T.J., Battegay, E.J., Hypoxia enhances vascular cell proliferation and angiogenesis in vitro via rapamycin (mTOR)-dependent signaling. FASEB J. 16 (2002), 771–780.
27. Kimura, S., Egashira, K., Chen, L., Nakano, K., Iwata, E., Miyagawa, M., Tsujimoto, H., Hara, K., Morishita, R., Sueishi, K., Tominaga, R., Sunagawa, K., Nanoparticle-mediated delivery of nuclear factor kappaB decoy into lungs ameliorates monocrotaline-induced pulmonary arterial hypertension. Hypertension 53 (2009), 877–883.
28. Kitterman, N., Poms, A., Miller, D.P., Lombardi, S., Farber, H.W., Barst, R.J., Bloodstream infections in patients with pulmonary arterial hypertension treated with intravenous prostanoids: insights from the REVEAL REGISTRY(R). Mayo Clin. Proc. 87 (2012), 825–834.
29. Krymskaya, V.P., Snow, J., Cesarone, G., Khavin, I., Goncharov, D.A., Lim, P.N., Veasey, S.C., Ihida-Stansbury, K., Jones, P.L., Goncharova, E.A., mTOR is required for pulmonary arterial vascular smooth muscle cell proliferation under chronic hypoxia. FASEB J. 25 (2011), 1922–1933.
30. Maeda, H., Nakamura, H., Fang, J., The EPR effect for macromolecular drug delivery to solid tumors: improvement of tumor uptake, lowering of systemic toxicity, and distinct tumor imaging in vivo. Adv. Drug Deliv. Rev. 65 (2013), 71–79.
31. Matsumura, Y., Maeda, H., A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res. 46 (1986), 6387–6392.
32. McLaughlin, V.V., McGoon, M.D., Pulmonary arterial hypertension. Circulation 114 (2006), 1417–1431.
33. Minnear, F.L., Barie, P.S., Malik, A.B., Effects of transient pulmonary hypertension on pulmonary vascular permeability. J. Appl. Physiol. Respir. Environ. Exerc. Physiol. 55 (1983), 983–989.
34. Mondesire, W.H., Jian, W., Zhang, H., Ensor, J., Hung, M.C., Mills, G.B., Meric-Bernstam, F., Targeting mammalian target of rapamycin synergistically enhances chemotherapy-induced cytotoxicity in breast cancer cells. Clin. Cancer Res. 10 (2004), 7031–7042.
35. Montani, D., Chaumais, M.C., Guignabert, C., Gunther, S., Girerd, B., Jais, X., Algalarrondo, V., Price, L.C., Savale, L., Sitbon, O., Simonneau, G., Humbert, M., Targeted therapies in pulmonary arterial hypertension. Pharmacol. Ther. 141 (2014), 172–191.
36. Morrell, N.W., Pulmonary hypertension due to BMPR2 mutation: a new paradigm for tissue remodeling?. Proc. Am. Thorac. Soc. 3 (2006), 680–686.
37. O'Brien, M.E., Wigler, N., Inbar, M., Rosso, R., Grischke, E., Santoro, A., Catane, R., Kieback, D.G., Tomczak, P., Ackland, S.P., Orlandi, F., Mellars, L., Alland, L., Tendler, C., Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Ann. Oncol. 15 (2004), 440–449.
38. Paddenberg, R., Stieger, P., von Lilien, A.L., Faulhammer, P., Goldenberg, A., Tillmanns, H.H., Kummer, W., Braun-Dullaeus, R.C., Rapamycin attenuates hypoxia-induced pulmonary vascular remodeling and right ventricular hypertrophy in mice. Respir. Res., 8, 2007, 15.
39. Pauwaa, S., Machado, R.F., Desai, A.A., Survival in pulmonary arterial hypertension: a brief review of registry data. Pulm. Circ. 1 (2011), 430–431.
40. Ruiz-Esparza, G.U., Segura-Ibarra, V., Cordero-Reyes, A.M., Youker, K.A., Serda, R.E., Cruz-Solbes, A.S., Amione-Guerra, J., Yokoi, K., Kirui, D.K., Cara, F.E., Paez-Mayorga, J., Flores-Arredondo, J.H., Guerrero-Beltran, C.E., Garcia-Rivas, G., Ferrari, M., Blanco, E., Torre-Amione, G., A specifically designed nanoconstruct associates, internalizes, traffics in cardiovascular cells, and accumulates in failing myocardium: a new strategy for heart failure diagnostics and therapeutics. Eur. J. Heart Fail. 18 (2016), 169–178.
41. Sahni, S., Ojrzanowski, M., Majewski, S., Talwar, A., Pulmonary arterial hypertension: a current review of pharmacological management. Pneumonol. Alergol. Pol. 84 (2016), 47–61.
42. Schermuly, R.T., Dony, E., Ghofrani, H.A., Pullamsetti, S., Savai, R., Roth, M., Sydykov, A., Lai, Y.J., Weissmann, N., Seeger, W., Grimminger, F., Reversal of experimental pulmonary hypertension by PDGF inhibition. J. Clin. Invest. 115 (2005), 2811–2821.
43. Seyfarth, H.J., Hammerschmidt, S., Halank, M., Neuhaus, P., Wirtz, H.R., Everolimus in patients with severe pulmonary hypertension: a safety and efficacy pilot trial. Pulm. Circ. 3 (2013), 632–638.
44. Smith, L.A., Cornelius, V.R., Plummer, C.J., Levitt, G., Verrill, M., Canney, P., Jones, A., Cardiotoxicity of anthracycline agents for the treatment of cancer: systematic review and meta-analysis of randomised controlled trials. BMC Cancer, 10, 2010, 337.
45. Somlyo, A.P., Somlyo, A.V., Ca2+ sensitivity of smooth muscle and nonmuscle myosin II: modulated by G proteins, kinases, and myosin phosphatase. Physiol. Rev., 83, 2003, 1325.
46. Stenmark, K.R., Fagan, K.A., Frid, M.G., Hypoxia-induced pulmonary vascular remodeling: cellular and molecular mechanisms. Circ. Res. 99 (2006), 675–691.
47. Tajsic, T., Morrell, N.W., Smooth muscle cell hypertrophy, proliferation, migration and apoptosis in pulmonary hypertension. Compr. Physiol. 1 (2011), 295–317.
48. Thomson, A.W., Turnquist, H.R., Raimondi, G., Immunoregulatory functions of mTOR inhibition. Nat. Rev. Immunol. 9 (2009), 324–337.
49. Valapour, M., Skeans, M.A., Smith, J.M., Edwards, L.B., Cherikh, W.S., Callahan, E.R., Israni, A.K., Snyder, J.J., Kasiske, B.L., Lung Am. J. Transpl. 16 (2016), 141–168.
50. Zhou, C., Townsley, M.I., Alexeyev, M., Voelkel, N.F., Stevens, T., Endothelial hyperpermeability in severe pulmonary arterial hypertension: role of store-operated calcium entry. Am. J. Physiol. Lung Cell. Mol. Physiol., 311, 2016, L560.